Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Diversity, equity and inclusion (DEI) are key to innovation, but the culture in the cardiovascular medical and research sector is often not supportive of diversity and collaboration.
As a Brazilian female cardiologist who has held leadership positions since my 40s, I understand the difficulties that women face in trying to achieve recognition and senior positions. I believe the awareness and joint efforts of both women and men can help build a more equitable future.
The proportion of female cardiologists is increasing in China, and they have special roles in clinical management and research. As the president of the Chinese Society of Cardiology, I believe female cardiologists excel in finding ways to balance family life with their career goals when they receive adequate support.
Women who are health providers face unique challenges when building their careers. Despite this, African female cardiologists should have a role in building equitable health systems and minimizing gender disparities in health care by mentoring girls and young women who aspire to a career in medicine and science.
When I have encountered obstacles in the three decades of my career, I have found that self-confidence and courage are the most effective traits for achieving my goals as a female cardiologist.
Mentorship is a crucial element to success and satisfaction among medical professionals. For a successful relationship, both mentors and mentees must examine their roles and goals. In this Comment article, a mentor–mentee pair discuss the necessary attributes for a productive partnership.
Bullying is common in cardiology and can have substantial adverse effects. However, bullying can be addressed by substantive leadership, organizational and individual efforts to build an inclusive and respectful culture.
Childbearing cardiologists face a number of challenges before, during and after pregnancy, including radiation concerns, infertility, pregnancy-related complications, and inadequate parental leave and return-to-work structures. Institutions can promote an equitable work environment by creating policies to mitigate these challenges.
Globally, Black people have some of the highest rates of cardiovascular disease. Racial inequities in cardiovascular health must be tackled. Black In Cardio is a trainee-led initiative aimed at promoting Black people in the cardiovascular field and raising awareness about issues related to the cardiovascular health of Black communities.
In patients with heart failure (HF) with mildly reduced or preserved ejection fraction, the SGLT2 inhibitor dapagliflozin reduces the risk of worsening HF or cardiovascular death by 18%, reduces total HF events and cardiovascular deaths by 23% and improves HF symptoms, according to findings from the DELIVER trial.
In the SECURE trial, a polypill containing aspirin, ramipril and atorvastatin taken within 6 months after myocardial infarction reduces the risk of major adverse cardiovascular events compared with usual care.
The addition of acetazolamide to loop diuretic therapy improves the success of decongestion in patients with acute decompensated heart failure and volume overload.
A new meta-analysis indicates that statin therapy causes a small excess of mostly mild muscle pain and that this risk is outweighed by the known cardiovascular benefits of treatment.
Among patients in a coma after resuscitation for out-of-hospital cardiac arrest, a restrictive versus liberal oxygenation strategy, or a target mean arterial blood pressure of 77 mmHg versus a target of 63 mmHg, did not affect the risk of neurological disability or death.
Extravascular implantable cardioverter–defibrillators are safe and effective at detecting and terminating ventricular arrhythmias induced at the time of implantation.
An invitation to undergo comprehensive cardiovascular screening in men aged 65–74 years did not lower the incidence of death from any cause after 5 years in the DANCAVAS trial, but data suggest benefits in some outcomes and in reducing mortality in men aged < 70 years.
In this Review, Quiles and Gustafsson compare the physiological and pathophysiological roles of mitochondrial fission and discuss the therapeutic potential of preventing excessive mitochondrial fission in the heart and vasculature.
In this Review, Khan and colleagues discuss the benefits and challenges of including pragmatism in the design, conduct and interpretation of randomized controlled trials (RCTs) for cardiovascular disease and highlight selected ongoing and completed cardiovascular RCTs that incorporate a pragmatic design.
Drugs can be repurposed for new therapeutic indications. In this Review, Mercola and colleagues summarize the latest techniques for systematic drug repurposing and re-engineering, which could increase the pace, efficiency and cost-effectiveness of drug discovery for the treatment of cardiovascular disease.
Cardiovascular researchers face a range of challenges, including reduced grant funding, job insecurity and a lack of diversity in leadership roles. In this Roadmap article, Marques and colleagues propose strategies to overcome these challenges, focusing on three key areas: capacity building, research funding and fostering diversity and equity.
